Computer Billing Standard

Publication
Article
OncologyONCOLOGY Vol 14 No 10
Volume 14
Issue 10

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing.

Physicians will have to use the “ANSI ASC X12N” electronic transmission format whenever they do computerized billing. The theory is that by using a single format (ANSI is the American National Standards Institute) instead of any of the 400 or so different ones kicking around today that a health plan might mandate, life will be simpler for physicians, and practice costs will decline precipitously. Medical practices with annual receipts over $5 million must be ANSI-compliant by October 2002. Those under that ceiling have until October 2003.

Articles in this issue
Computer Technology Helps Radiologists Spot Overlooked Small Breast Cancers
New Awards Spotlight Courage of Cancer Survivors
Using the Body’s Anticancer Defenses to Guide and Improve Breast Cancer Treatment
Vaccine Studies Demonstrate Promise of Immunotherapy to Treat Breast Cancer and Prevent Recurrence
Children’s Art Project at M. D. Anderson Cancer Center
Settling on an Increased NCI Budget
Computer Billing Standard
Ligand Receives FDA Marketing Clearance for Bexarotene Gel
Mayo Clinic Study Shows Patients Uncertain About Cancer Risk Terms
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Commentary (Stenson): Indications for Selective Neck Dissection: When, How, and Why
Follow-up Care for Cancer: Making the Benefits Equal the Cost
Costs of Smoking Among Active-Duty US Air Force Personnel—United States, 1997
Multidisciplinary Management of Pediatric Soft-Tissue Sarcoma

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
CancerNetwork® spoke with Neha Mehta-Shah, MD, MSCI, about the clinical landscape for patients undergoing treatment for rare lymphomas.
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Related Content
Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Ibrilatazar Shows Survival Improvement in Advanced Squamous NSCLC

Roman Fabbricatore
June 6th 2025
Article

Following the induction phase with chemotherapy alone, ibrilatazar has shown a manageable toxicity profile in patients with advanced squamous NSCLC.

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Twice Daily, Hyperfractionated Thoracic Radiotherapy Effective at 60 Gy in SCLC

Tim Cortese
June 6th 2025
Article

A phase 2 trial demonstrated a median overall survival of 43.5 months at 60 Gy compared with 22.5 months at 45 Gy in patients with limited-stage SCLC.

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

Exploring Burnout Causes and Management in Oncologic Practice

Eric P. Winer, MD
June 2nd 2025
Podcast

Professor of Pharmacology, Eric Winer, MD, spoke about a publication he authored exploring the state of oncologist burnout and how it impacts practice.

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

THIO Plus Cemiplimab Associated with Prolonged OS in ICI-Resistant NSCLC

Gina Mauro
June 5th 2025
Article

THIO with cemiplimab is active and well-tolerated in patients with advanced non–small cell lung cancer resistant to immune checkpoint inhibitors in second- and third-line settings.

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

High Responses With BNT327/PM8002 Plus Chemo in Mesothelioma

Ashling Wahner
June 5th 2025
Article

Frontline BNT327/PM8002 plus chemotherapy led to a confirmed ORR of 51.6% and a DCR of 90.3% in patients with unresectable pleural and peritoneal mesothelioma.